Paech, Daniel http://orcid.org/0000-0001-5755-6833
Dreher, Constantin
Regnery, Sebastian
Meissner, Jan-Eric
Goerke, Steffen
Windschuh, Johannes
Oberhollenzer, Johanna
Schultheiss, Miriam
Deike-Hofmann, Katerina
Bickelhaupt, Sebastian
Radbruch, Alexander
Zaiss, Moritz
Unterberg, Andreas
Wick, Wolfgang
Bendszus, Martin
Bachert, Peter
Ladd, Mark E.
Schlemmer, Heinz-Peter
Article History
Received: 3 November 2018
Revised: 28 December 2018
Accepted: 4 February 2019
First Online: 26 February 2019
Compliance with ethical standards
:
: The scientific guarantor of this publication is Dr. Daniel Paech.
: The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: Prof. Dr. Annette Kopp-Schneider (Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany) kindly provided statistical advice for this manuscript.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained.
: The study cohort has previously been reported (Paech et al. Neuro Oncol, 2018, noy073 and Regnery et al. Oncotarget, 2018, 9:28772–28783) and a subcohort of eleven patients has been included in methodical publications (Zaiss et al. Neuroimage, 2015, 112:180–188 and Zaiss et al. MRM, 2017, 77(1):196–208). However, no investigations of overall survival and progression-free survival have previously been performed.
: • prospective• diagnostic or prognostic• performed at one institution